Kiniksa Pharmaceuticals International, PLC Form 4 insider transactions

John F. Paolini, CHIEF MEDICAL OFFICER of Kiniksa Pharmaceuticals International, plc, reported multiple transactions in common stock on September 1, 2026.

Barry D Quart, a Director of Kiniksa Pharmaceuticals International, plc, reported a transaction in 2,600 shares of common stock on August 19, 2026.

Richard S Levy, a Director of Kiniksa Pharmaceuticals International, plc, reported multiple transactions in common stock on August 1, 2026.

G Bradley Cole, a Director of Kiniksa Pharmaceuticals International, plc, sold 3,673 shares of common stock on July 29, 2026 for $81.43 per share.

Dhiraj H. Malkani, Chief Strategy Officer at Kiniksa Pharmaceuticals, was granted stock options and restricted share units on July 1, 2026.

Barry D. Quart, a Director at Kiniksa Pharmaceuticals International, plc, reported transactions involving Class A Ordinary Shares, including the acquisition of shares through vested Restricted Stock Units and the exercise of stock options.

Director Kimberly J. Popovits reported transactions involving Class A Ordinary Shares and stock options for Kiniksa Pharmaceuticals International, plc.

Sanj K. Patel, Chairman & CEO of Kiniksa Pharmaceuticals, reported a significant transaction involving Class A and Class B Ordinary Shares.

Tracey L. McCain, a Director at Kiniksa Pharmaceuticals International, plc, reported transactions involving Class A Ordinary Shares, including the acquisition of shares and the vesting of options and restricted stock units.

Kiniksa Pharmaceuticals International, plc director Thomas Malley reported transactions involving Class A Ordinary Shares, including the acquisition of shares and options.

Richard S. Levy, a Director at Kiniksa Pharmaceuticals International, plc, reported transactions involving Class A Ordinary Shares, including the acquisition of shares via options and restricted stock units.

Director G. Bradley Cole reported transactions involving Class A Ordinary Shares and derivative securities of Kiniksa Pharmaceuticals International, plc.

Kiniksa Pharmaceuticals International, plc reports a Form 4 filing detailing stock transactions by Chief Medical Officer John F. Paolini.

Kiniksa Pharmaceuticals CEO Sanj Patel exercised options and sold shares under a pre-arranged 10b5-1 trading plan.

Michael R. Megna, Chief Accounting Officer at Kiniksa Pharmaceuticals International, plc, reported a transaction involving Class A Ordinary Shares.

Moat Ross, Chief Operating Officer of Kiniksa Pharmaceuticals, reported a sale of 1,703 Class A Ordinary Shares on April 9, 2026, for $46.69 per share, executed under a Rule 10b5-1 trading plan.

Eben Tessari, Chief Strategy Officer at Kiniksa Pharmaceuticals, reported transactions involving Class A Ordinary Shares and Restricted Share Units.

Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals, reported transactions involving Class A Ordinary Shares and Restricted Share Units.

Kiniksa Pharmaceuticals Chairman & CEO Sanj K. Patel reported transactions involving Class A Ordinary Shares, including sales and acquisitions under a 10b5-1 plan.

John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals International, plc, reported transactions involving Class A Ordinary Shares and Restricted Share Units.

Kiniksa Pharmaceuticals International, plc reports on insider transactions involving Class A Ordinary Shares and Restricted Share Units.

Michael R. Megna, Chief Accounting Officer at Kiniksa Pharmaceuticals, reported transactions involving Class A Ordinary Shares and Restricted Share Units.

Barry D. Quart, a Director at Kiniksa Pharmaceuticals International, plc, reported transactions involving Class A Ordinary Shares, including acquisitions and dispositions under a 10b5-1 plan.

Eben Tessari, Chief Strategy Officer at Kiniksa Pharmaceuticals, reports on recent transactions involving Class A Ordinary Shares, including acquisitions and grants of equity awards.

Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals, reported transactions involving Class A Ordinary Shares, including the acquisition of shares and options.

Sanj K. Patel, Chairman & CEO of Kiniksa Pharmaceuticals, reported significant transactions involving Class A Ordinary Shares, including acquisitions and dispositions of vested and unvested equity.

John Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals, reported transactions involving Class A Ordinary Shares, including the acquisition of shares and the grant of options and restricted share units.

Kiniksa Pharmaceuticals International, plc executive Moat Ross reports on recent transactions involving Class A Ordinary Shares, including acquisitions and dispositions of various equity awards.

Michael R. Megna, Chief Accounting Officer at Kiniksa Pharmaceuticals, reported several transactions involving Class A Ordinary Shares, including acquisitions and dispositions of securities.

Kiniksa Pharmaceuticals' Chief Medical Officer, John F. Paolini, sold 40,000 Class A Ordinary Shares following the exercise of options, reducing his direct beneficial ownership.